Determinant factors of treatment adherence in Parkinson’s disease
Objective: To determine factors predicting treatment adherence in patients with idiopathic Parkinson’s disease. Background: Parkinson’s disease is the second most common cause of neurodegenerative disease…Cognitive and demographic predictors of progression to MCI and dementia in Parkinson’s disease
Objective: To determine the association between demographic and cognitive features and subsequent progression of cognitive symptoms in Parkinson’s disease (PD). Background: Most patients diagnosed with…Rotenone induces astrocyte-mediated non-cell autonomous dopaminergic neurotoxicity
Objective: In this study, we examined involvement of astrocytes in rotenone-induced dopaminergic neurotoxicity using primary cultured cells. Background: Several studies reported that pesticide exposure, such…Intention Awareness in Parkinson’s Disease
Objective: To investigate the role of dopamine in intention awareness of voluntary actions in patients with Parkinson’s Disease (PD). Background: Underactivation of the SMA due…SNCA multiplication consortium: Clinicogenetic analysis of SNCA multiplication probands and families.
Objective: Clinicogenetic analysis of 57 affected probands with SNCA multiplication, 3 unaffected carriers, and their 60 families. To use informative pedigrees to identify penetrance modifiers…Parkinsonian Features in a Cohort of Gaucher’s Disease (GD) Patients and Relatives.
Objective: to investigate the prevalence and clinical features of parkinsonism in a cohort of 21 GD patients and their relatives. Background: GD is a lysosomal…Short term effects of bilateral STN DBS on psychiatric profile in Parkinson’s disease
Objective: We intend to look into the effects of bilateral STN DBS on Psychiatric profile of Parkinson’s patients. Background: Parkinson’s disease is a well-known degenerative…Assessing Bone Health in Parkinson’s – When and how?
Objective: To assess the impact of, and practicality of, assessing bone health routinely in people newly diagnosed with Parkinson’s disease in a South Wales University…PROMESA: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach – evaluation of serious adverse events
Objective: In the PROMESA trial (ClinicalTrials Identifier: NCT02008721) Epigallocatechingallate (EGCG) a catechine that prevents pathological protein aggregation in vitro and can be purified from green…The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey
Objective: The movement disorders society task force for the Middle East (MDS-Task Force for the Middle East) conducted a survey with an aim of characterizing…
- « Previous Page
- 1
- …
- 281
- 282
- 283
- 284
- 285
- …
- 388
- Next Page »